Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 0.6× sales vs its 4.5× historical median P/S.
Fair value ≈ $10.46 · price $1.29 today
Undervalued · 88% below
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$AKYA Excellent article that nails exactly where AKYA stands right now. So if you want to update your AKYA knowledge or get acquainted with AKYA, this is a must read. https://beyondspx.com/article/akoya-biosciences-spatial-biology-leadership-amidst-macro-headwinds-and-strategic-pivots-nasdaq-akya
$AKYA completes merger with Quanterix - shares converted at 0.1461 $QTRX + $0.38 cash. Trading halted, delisting from Nasdaq effective immediately. While the deal provides liquidity relief, investors now face integration risks and diluted exposure. Proceed with caution - this was a survival move, not a growth story.
https://www.sec.gov/Archives/edgar/data/1711933/000110465925066306/tm2520065d1_8k.htm
Intrigant value
$AKYA $0.5261 per share.
*DAC (dollar average cost) $2.28 (6.12.24).
Co announced that it has completed its previously announced acquisition of Akoya Biosciences, Inc., establishing a scaled leader in the early detection of disease for the neurology, oncology and immunology markets.
Under the terms of the amended merger agreement announced on April 29th, Quanterix issued approximately 7.8 million shares of its common stock and paid approximately $20 million in cash, in the aggregate, to holders of Akoya shares and other Akoya equity awards.
As previously announced, Masoud Toloue and Vandana Sriram will continue to serve as Chief Executive Officer and Chief Financial Officer of the combined company.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
$AKYA NASDAQ Equity Corporate Actions Alert #2025 - 355
Information Regarding the Merger of Akoya Biosciences, Inc. (AKYA)
https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-355
At a special meeting held on July 7, 2025, the shareholders of Akoya Biosciences, Inc. (AKYA) will vote on the proposed merger with Quanterix Corp ($QTRX). If approved, the proposed merger is tentatively scheduled to close prior to the market open on July 8, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on July 7, 2025. If the merger closes as anticipated, the stock will remain halted on the day of closing (July 8th) and will be suspended effective July 9, 2025.
Merger consideration: AKYA shareholders will receive $0.38 in cash and 0.1461 shares of QTRX for each share of AKYA held.
$AKYA considering it says this stock is 70 percent owned by the insiders I would have to assume a sweet cash offer would be tempting since the insiders own 73 percent of the 50 million outstanding shares ……
$AKYA 11:45 AM EDT, 05/21/2025 (MT Newswires) -- Akoya Biosciences(AKYA) said in a Wednesday filing that it received an unsolicited acquisition proposal from an undisclosed third party, which offered $1.40 in cash for each Akoya common share.
